Ronald de Wit

42.0k total citations · 10 hit papers
373 papers, 26.4k citations indexed

About

Ronald de Wit is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Ronald de Wit has authored 373 papers receiving a total of 26.4k indexed citations (citations by other indexed papers that have themselves been cited), including 177 papers in Oncology, 172 papers in Pulmonary and Respiratory Medicine and 168 papers in Surgery. Recurrent topics in Ronald de Wit's work include Prostate Cancer Treatment and Research (152 papers), Bladder and Urothelial Cancer Treatments (98 papers) and Cancer Immunotherapy and Biomarkers (79 papers). Ronald de Wit is often cited by papers focused on Prostate Cancer Treatment and Research (152 papers), Bladder and Urothelial Cancer Treatments (98 papers) and Cancer Immunotherapy and Biomarkers (79 papers). Ronald de Wit collaborates with scholars based in Netherlands, United States and France. Ronald de Wit's co-authors include Mario A. Eisenberger, Ian F. Tannock, Kim N., Christine Théodore, Stéphane Oudard, Mark Rosenthal, A Płużańska, Nicholas D. James, J Horti and Ingela Turesson and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Communications.

In The Last Decade

Ronald de Wit

363 papers receiving 25.8k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer

2004 4.3k citations Ian F. Tannock, Ronald de Wit et al. profile →
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

2012 3.3k citations Fred Saad, Ronald de Wit et al. profile →
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

2017 2.4k citations Joaquim Bellmunt, Ronald de Wit et al. profile →
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study

2017 939 citations Ronald de Wit, Joaquim Bellmunt et al. profile →
Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study

2008 820 citations Ronald de Wit, Mario A. Eisenberger et al. Journal of Clinical Oncology profile →
The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin—The Aprepitant Protocol 052 Study Group

2003 593 citations Ronald de Wit et al. Journal of Clinical Oncology profile →
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986

2011 523 citations Maria De Santis, Joaquim Bellmunt et al. Journal of Clinical Oncology profile →
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer

2019 377 citations Ronald de Wit, Johann S. de Bono et al. profile →
Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

2021 329 citations Joost L. Boormans, Ronald de Wit et al. profile →
Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

2019 306 citations Joaquim Bellmunt, Ronald de Wit et al. profile →

Peers

Countries citing papers authored by Ronald de Wit

Since Specialization

Citations

This map shows the geographic impact of Ronald de Wit's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronald de Wit with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronald de Wit more than expected).

Fields of papers citing papers by Ronald de Wit

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronald de Wit. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronald de Wit. The network helps show where Ronald de Wit may publish in the future.

Co-authorship network of co-authors of Ronald de Wit

This figure shows the co-authorship network connecting the top 25 collaborators of Ronald de Wit. A scholar is included among the top collaborators of Ronald de Wit based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronald de Wit. Ronald de Wit is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer—A Patient Cohort Analysis 2025 ·European Urology Oncology ·Debbie Robbrecht, (unknown), John W.M. Martens, Maureen J.B. Aarts, Paul Hamberg, Michiel S. van der Heijden, Jens Voortman, Niven Mehra, Hans M. Westgeest, Ronald de Wit, Reno Debets, Joost L. Boormans, (unknown)	1
2	Darolutamide does not interfere with OATP‐mediated uptake of docetaxel 2024 ·International Journal of Cancer ·(unknown), Zahra Talebi, (unknown), Yan Jin, Alice A. Gibson, Peng Hu, Peter de Bruijn, Corrina M.A. de Ridder, Debra Stuurman, Shuiying Hu, Wytske M. van Weerden, Stijn L.W. Koolen, Ronald de Wit, Alex Sparreboom, Ron H.J. Mathijssen, Eric D. Eisenmann	3
3	mFast‐SeqS‐based aneuploidy score in circulating cell‐free DNA is a prognostic biomarker in prostate cancer 2023 ·Molecular Oncology ·(unknown), Bianca Mostert, (unknown), Jaco Kraan, Vanja de Weerd, Esther Oomen‐de Hoop, Paul Hamberg, Brigitte C.M. Haberkorn, Helgi H. Helgason, Ronald de Wit, Ron H.J. Mathijssen, Martijn P. Lolkema, Saskia M. Wilting, Job van Riet, John W.M. Martens	5
4	The CHASIT study: sequential chemo-immunotherapy in patients with locally advanced urothelial cancer – a non-randomized phase II clinical trial 2023 ·BMC Cancer ·(unknown), Yazan Al Salhi, Debbie Robbrecht, Ronald de Wit, Geert J.L.H. van Leenders, Tahlita C.M. Zuiverloon, Joost L. Boormans	1
5	Liquid Biopsies for Early Response Evaluation of Radium-223 in Metastatic Prostate Cancer 2023 ·JCO Precision Oncology ·(unknown), (unknown), (unknown), Vanja de Weerd, (unknown), Jaco Kraan, John W.M. Martens, Niven Mehra, Paul Hamberg, Martijn P. Lolkema, Ronald de Wit, Astrid A.M. van der Veldt, Saskia M. Wilting	1
6	Flow‐based immunomagnetic enrichment of circulating tumor cells from diagnostic leukapheresis product 2023 ·Molecular Oncology ·Michiel Stevens, Anouk Mentink, Frank Coumans, (unknown), (unknown), Jaco Kraan, Ronald de Wit, John W.M. Martens, Leon W.M.M. Terstappen	2
7	Real-world evidence of patients with metastatic castration-resistant prostate cancer treated with cabazitaxel: comparison with the randomized clinical study CARD 2022 ·Prostate Cancer and Prostatic Diseases ·Ronald de Wit, Stephen J. Freedland, Stéphane Oudard, Georgi K. Marinov, (unknown), Austin J. Combest, (unknown), Ayse Ӧzatılgan, Alicia K. Morgans	7
8	Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study 2021 ·Cancers ·Nicolas Delanoy, Debbie Robbrecht, Mario A. Eisenberger, Oliver Sartor, Ronald de Wit, Florence Mercier, Christine Geffriaud-Ricouard, Johann S. de Bono, Stéphane Oudard	5
9	Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study 2020 ·Clinical Cancer Research ·Edwin M. Posadas, Kim N., Ronald de Wit, Maja J.A. de Jonge, Gerhardt Attard, Terence W. Friedlander, Margaret K. Yu, Peter Hellemans, Caly Chien, (unknown), (unknown), Fred Saad	12
10	Incidence of metachronous contralateral testicular germ cell tumour and association with chemotherapy 2020 ·European Urology Open Science ·(unknown), (unknown), (unknown), Ronald de Wit, Jourik A. Gietema, Gerard Groenewegen, J.A. Witjes, Hetty A. van den Berg, Janine Nuver, Jacqueline M. Tromp, (unknown), Tineke J. Smilde, Maureen J.B. Aarts, Ben Vanneste, J.L.H. Ruud Bosch, Simon Horenblas, Michael Schaapveld, Richard P. Meijer	0
11	Use of Chemotherapy and Androgen Signaling–targeted Inhibitors in Patients with Metastatic Prostate Cancer 2020 ·European Urology ·Ronald de Wit, Bertrand Tombal, Stephen J. Freedland	5
12	Effects of Budesonide on Cabazitaxel Pharmacokinetics and Cabazitaxel-Induced Diarrhea: A Randomized, Open-Label Multicenter Phase II Study 2016 ·Clinical Cancer Research ·Annemieke J.M. Nieuweboer, Anne‐Joy M. de Graan, Paul Hamberg, Sander Bins, Robert J. van Soest, Robbert J. van Alphen, Andries M. Bergman, Aart Beeker, Henk van Halteren, Albert J. ten Tije, (unknown), (unknown), Dana Chiţu, Ronald de Wit, Ron H.J. Mathijssen	12
13	Dynamical seasonal prediction of climate extremes in the Pacific 2013 ·Piantadosi, J., Anderssen, R.S. and Boland J. (eds) MODSIM2013, 20th International Congress on Modelling and Simulation ·(unknown), (unknown), (unknown), Ronald de Wit, (unknown), (unknown), Claire M. Spillman, Harry H. Hendon, Peter C. McIntosh, Toshiyuki Nakaegawa, (unknown), (unknown), (unknown), (unknown), John Church, D. A. Jones, Yuriy Kuleshov, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
14	Randomized Phase III Study Comparing Paclitaxel–Bleomycin, Etoposide, and Cisplatin (BEP) to Standard BEP in Intermediate-Prognosis Germ-Cell Cancer: Intergroup Study EORTC 30983 2012 ·Journal of Clinical Oncology ·Ronald de Wit, Iwona Skoneczna, Gedske Daugaard, Maria De Santis, August Garin, Nina Aass, Alfred Witjes, Peter Albers, (unknown), J. R. Germa-Lluch, Sandrine Marréaud, Laurence Collette	47
15	Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987 2012 ·Journal of Clinical Oncology ·Joaquim Bellmunt, Hans von der Maase, Graham M. Mead, Iwona Skoneczna, Maria De Santis, Gedske Daugaard, Andreas Boehle, Christine Chevreau, Luis Paz‐Ares, Leslie R. Laufman, Eric Winquist, Derek Raghavan, Sandrine Marréaud, Sandra Collette, Richard Sylvester, Ronald de Wit	324
16	Prediction of Survival following First-Line Chemotherapy in Men with Castration-Resistant Metastatic Prostate Cancer 2009 ·Clinical Cancer Research ·Andrew J. Armstrong, Elizabeth Garrett‐Mayer, Ronald de Wit, Ian F. Tannock, Mario A. Eisenberger	166
17	Randomized Phase II/III Trial Assessing Gemcitabine/ Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy: Phase II—Results of EORTC Study 30986 2009 ·Journal of Clinical Oncology ·Maria De Santis, Joaquim Bellmunt, Graham M. Mead, J. Martijn Kerst, Michael Leahy, Pablo Maroto, Iwona Skoneczna, Sandrine Marréaud, Ronald de Wit, Richard Sylvester	123
18	A Contemporary Prognostic Nomogram for Men with Hormone-Refractory Metastatic Prostate Cancer: A TAX327 Study Analysis 2007 ·Clinical Cancer Research ·Andrew J. Armstrong, Elizabeth Garrett‐Mayer, (unknown), Ronald de Wit, Ian F. Tannock, Mario A. Eisenberger	282
19	Long-term risk of non-germ cell malignancies in 5-year survivors of testicular cancer 2005 ·Data Archiving and Networked Services (DANS) ·Flora E. van Leeuwen, Alexandra W. van den Belt‐Dusebout, Gabey M. Ouwens, Ronald de Wit, Jourik A. Gietema, Simon Horenblas, J. G. Ribot, Marieke W.J. Louwman, Berthe M.P. Aleman	1
20	Is 3BEP equivalent to 3BEP+1EP in good prognosis germ cell cancer? An EORTC/MRC phase III study 1999 ·UCL Discovery (University College London) ·Ronald de Wit, (unknown), Paul Wilkinson, PHM de Mulder, G.M. Mead, S.D. Fosså, PS Cook, Linda de Prijck, Sally Stenning, Laurence Collette	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact